Published in Cancer on August 15, 2005
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol (2009) 1.06
Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today (2013) 1.01
Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol (2006) 0.96
Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer (2011) 0.93
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol (2011) 0.89
Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol (2015) 0.89
Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines. Int J Radiat Oncol Biol Phys (2014) 0.86
Liver transplantation in the setting of hepatocellular carcinoma and portal vein thrombosis: a challenging dilemma? Dig Dis Sci (2007) 0.85
Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation. J Cancer Res Clin Oncol (2008) 0.83
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine (Baltimore) (2016) 0.81
The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Gastroenterol (2011) 0.79
Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection. HPB (Oxford) (2012) 0.79
A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol (2013) 0.79
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol (2016) 0.76
Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med (2016) 0.75
Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol (2017) 0.75
Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol (2005) 2.64
A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2009) 2.06
Limited thymectomy for stage I or II thymomas. Lung Cancer (2009) 1.64
Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol (2007) 1.53
Calculation of rotational setup error using the real-time tracking radiation therapy (RTRT) system and its application to the treatment of spinal schwannoma. Int J Radiat Oncol Biol Phys (2002) 1.52
Clinical Results of Carbon Ion Radiotherapy at NIRS. J Radiat Res (2007) 1.49
Arcuate fasciculus tractography integrated into Gamma Knife surgery. J Neurosurg (2009) 1.47
Telomerase activity and expression of human telomerase catalytic subunit gene in esophageal tissues. J Gastroenterol (2002) 1.47
Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res (2010) 1.46
Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone. J Gastroenterol (2005) 1.43
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res (2008) 1.39
Overview of epidermolysis bullosa. J Dermatol (2010) 1.37
Correlation between the respiratory waveform measured using a respiratory sensor and 3D tumor motion in gated radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.33
Sugar micro needles as transdermic drug delivery system. Biomed Microdevices (2005) 1.28
Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int J Radiat Oncol Biol Phys (2003) 1.24
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res (2005) 1.24
Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol (2004) 1.24
Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol (2010) 1.24
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res (2015) 1.23
Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol (2010) 1.18
Transcriptional regulation and characterization of the promoter region of the human ABCC6 gene. J Invest Dermatol (2006) 1.17
Prognostic factors and a scoring system for survival after radiotherapy for metastases to the spinal column: a review of 544 patients at Shizuoka Cancer Center Hospital. Cancer (2008) 1.17
Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys (2007) 1.15
Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol (2012) 1.14
Cholesterol 25-hydroxylation activity of CYP3A. J Lipid Res (2011) 1.11
Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol (2008) 1.10
Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys (2005) 1.10
First clinical cone-beam CT imaging during volumetric modulated arc therapy. Radiother Oncol (2008) 1.09
Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol (2009) 1.06
Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatology (2006) 1.06
Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys (2005) 1.05
Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.05
Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. J Hepatol (2005) 1.05
Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys (2004) 1.05
Proton beam therapy interference with implanted cardiac pacemakers. Int J Radiat Oncol Biol Phys (2008) 1.04
A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol (2006) 1.04
Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys (2010) 1.04
Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2009) 1.04
Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer (2009) 1.03
Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys (2010) 1.03
Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.02
Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. J Lipid Res (2008) 1.02
Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2012) 1.01
Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci (2005) 1.01
Ammonia-induced apoptosis is accelerated at higher pH in gastric surface mucous cells. Am J Physiol Gastrointest Liver Physiol (2002) 1.01
Pathologic radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol (2008) 1.01
Highly sensitive quantification of 7alpha-hydroxy-4-cholesten-3-one in human serum by LC-ESI-MS/MS. J Lipid Res (2006) 1.00
Radiotherapy for patients with symptomatic intramedullary spinal cord metastasis. J Radiat Res (2011) 1.00
Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol (2007) 1.00
Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res (2005) 0.99
Successful treatment of lymphadenosis benigna cutis with topical photodynamic therapy with delta-aminolevulinic acid. Dermatology (2005) 0.99
Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 0.99
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol (2013) 0.99
Comparison of the effects of high-energy photon beam irradiation (10 and 18 MV) on 2 types of implantable cardioverter-defibrillators. Int J Radiat Oncol Biol Phys (2012) 0.98
Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res (2007) 0.97
Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol (2013) 0.97